CareDx: Titte Srinivas, Steven Stone, Dustin Leach, Martyn Edney, More
CareDx has appointed Titte Srinivas as vice president of digital development and clinical integration, Steven Stone as VP of KidneyCare, Dustin Leach as VP of customer experience, and Martyn Edney as senior VP and head of human resources.
Srinivas is a transplant nephrologist who joins CareDx from University Hospitals in Cleveland, where he served as the chief of the division of nephrology and hypertension and Peter B. DeOreo Chair in Nephrology and Dialysis. Stone joins CareDx from from Myriad Genetics, where he served as VP of cancer genomics and developed products for personalized medicine in oncology. Leach joins CareDx from Teva Pharmaceuticals, where he most recently served as senior director of patient services – program development. Edney joins CareDx from Iqvia, where he served as VP of HR for the US and Canada.
The company also announced that it has promoted Marica Grskovic to VP of cell transplant therapy, and Jere Ramsey-Lester to VP of HR.
Grskovic joined CareDx nine years ago and has played a role in overseeing the design and development of the company's transplant diagnostic tests. Ramsey-Lester has been with CareDx since 2019, and has served as interim head of HR for the past year. She has held leadership positions in human resources at TreeHouse Foods, ConAgra Foods, and Fiserv.
BioSkryb: Sean Keohane
BioSkryb has appointed Sean Keohane as senior vice president of commercial operations to spearhead commercialization of the company's ResolveDNA products for singe-cell whole-genome amplification. Keohane previously was VP of US marketing and sales at Numares. He has also previously held a variety of sales, marketing, and management positions at companies such as Molecular Devices, Thermo Fisher Scientific, Qiagen, Ciphergen Biosystems, Ventana Medical Systems, and Roche.
Oxford Nanopore Technologies: Tim Cowper, Jordan Herman
Tim Cowper has become CFO and Jordan Herman general counsel of Oxford Nanopore Technologies.
Chowper joined the company in 2012 as commercial operations director after acting as interim finance director for several months in 2009. He became VP of finance in 2017. Previously, he was finance director at British Biotech and at Clipper Ventures, he cofounded Sterilox, and he was financial controller at Celltech.
Herman joins Oxford Nanopore from Baker Botts, where he was a partner and acted as Oxford's outside counsel for more than a decade. He holds a JD from Ohio State University and a degree in political economy from Washington University.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.